In Stock
Cjc-1295 Dac
10mg
COA with every batch
Limited Quantity
GHRH Receptor Binding & Sustained GH Release
CJC-1295 with DAC is a focus for researchers studying the somatotropic axis. It engages GHRH receptors in the anterior pituitary to stimulate growth hormone synthesis and release. The Drug Affinity Complex enables covalent binding to circulating albumin, extending functional activity to several days. Studies use this property to model continuous, non-pulsatile somatotropic stimulation and how it differs from the short bursts produced by native GHRH.
Serum Albumin Conjugation & Half-Life
In peptide research, CJC-1295 DAC is investigated for the mechanics of its albumin-binding modification. Researchers study how the DAC moiety protects the peptide from enzymatic degradation and renal clearance, examining the pharmacokinetic basis for its extended duration of action within preclinical models.
Metabolic & Somatotropic Axis Effects
Recent studies have utilized CJC-1295 DAC to investigate downstream effects on the GH/IGF-1 axis. By examining how prolonged somatotropic signaling influences lipid metabolism, protein synthesis, and substrate utilization, researchers explore the distinction between chronic and acute hormonal exposure in metabolic models.
Supplied as a purified, lyophilized powder, it is intended strictly for laboratory research; it is not for human or veterinary administration.
For research use only.
CJC-1295 DAC is a synthetic Growth Hormone-Releasing Hormone (GHRH) analog designed with a Drug Affinity Complex (DAC) to extend its duration of action. It is widely studied for its effects on the somatotropic axis and growth hormone signaling.
Yes. CJC-1295 DAC is a synthetic peptide engineered to bind GHRH receptors while utilizing a Drug Affinity Complex to prolong its activity in laboratory research.
CJC-1295 DAC is commonly investigated in studies involving growth hormone secretion, the GH/IGF-1 axis, peptide pharmacokinetics, protein synthesis, lipid metabolism, and somatotropic signaling.
CJC-1295 DAC should be stored in a cool, dry environment. For long-term stability, lyophilized vials are typically kept frozen and protected from heat, moisture, and direct sunlight.
CJC-1295 DAC is unique for its Drug Affinity Complex (DAC), which enables binding to serum albumin and significantly extends its functional half-life, making it an ideal research peptide for studying sustained growth hormone release and prolonged somatotropic signaling.
Overview
GHRH Receptor Binding & Sustained GH Release
CJC-1295 with DAC is a focus for researchers studying the somatotropic axis. It engages GHRH receptors in the anterior pituitary to stimulate growth hormone synthesis and release. The Drug Affinity Complex enables covalent binding to circulating albumin, extending functional activity to several days. Studies use this property to model continuous, non-pulsatile somatotropic stimulation and how it differs from the short bursts produced by native GHRH.
Serum Albumin Conjugation & Half-Life
In peptide research, CJC-1295 DAC is investigated for the mechanics of its albumin-binding modification. Researchers study how the DAC moiety protects the peptide from enzymatic degradation and renal clearance, examining the pharmacokinetic basis for its extended duration of action within preclinical models.
Metabolic & Somatotropic Axis Effects
Recent studies have utilized CJC-1295 DAC to investigate downstream effects on the GH/IGF-1 axis. By examining how prolonged somatotropic signaling influences lipid metabolism, protein synthesis, and substrate utilization, researchers explore the distinction between chronic and acute hormonal exposure in metabolic models.
Supplied as a purified, lyophilized powder, it is intended strictly for laboratory research; it is not for human or veterinary administration.
For research use only.
Trusted by 150+ Customers
60-day money-back guaranteeon every order
